Human Vaccines Project presents initial findings from first clinical trials

December 1, 2017, Human Vaccines Project

Scientists leading the clinical programs for the Human Vaccines Project reported today high-level outcomes from two concurrent clinical studies aimed at deciphering the components and mechanisms used by the human immune system to prevent and control disease at the World Vaccine and Immunotherapy Congress in San Diego, Calif. The findings from the studies may provide important new insights on human immunity that the Human Vaccines Project - a public-private partnership aimed at decoding the immune system to advance human health - will leverage to launch expanded studies in 2018.

The Project's first program, the Human Immunome Program, aims to identify the core components that exist across everyone's immune systems and utilize this information to enable development of new and improved vaccines. The team is sequencing millions of recombined and expressed B and T cell genes in healthy adults and cord blood samples at an unprecedented depth, seeking to identify shared elements of the human immune system not previously recognized. The team is led by James E. Crowe, Jr., MD, Director of Vanderbilt University Medical Center's Vaccine Center, the scientific hub of the Human Immunome Program.

"We are studying the immune systems of healthy individuals to identify common elements, which could be important for facilitating new and improved vaccines," explained Dr. Crowe. "We also plan to expand these studies to complete the catalog across different demographics and geographies and compare healthy subjects with individuals with immune-mediated diseases such as multiple sclerosis, cancer and Alzheimer's, which could also reveal novel diagnostic markers."

Early findings from a second and complementary clinical research program of the Human Vaccines Project, aimed at revealing the key principles or rules that the human immune system follows when it comes to the prevention and control of disease, will be shared in two separate presentations by Manish Sadarangani, MD, PhD, Director of the Vaccine Evaluation Center of the University of British Columbia and BC Children's Hospital Research Institute and Richard Scheuermann, PhD, Director, J. Craig Venter Institute. The long-term goal of this program is to understand the rules of the human immune system that will enable one-shot vaccines to provide long term protective immunity in all populations. The aim of this study is to understand why some people respond effectively to a single immunization of a licensed Hepatitis B vaccine, while others require up to three immunizations for generating protective immunity.

Using novel artificial intelligence and machine-learning techniques to analyze large sets of data, the team sought to determine if activation of marker genes from innate immune cells - non-specific defense mechanisms - would distinguish between responders to vaccines and non-responders.

Preliminary data, comparing three HepB vaccine responders to three non-responders showed that activation of marker genes in subsets of innate immune cells could predict those people that made detectable serum antibody responses against HepB vaccine after a single immunization.

"These preliminary data points toward strategies to understand why some people respond better to vaccines than others," suggested Dr. Sadarangani. "We plan to expand this trial to include populations of all ages across all resource settings to provide the most comprehensive analysis of any vaccine ever undertaken."

"Using single cell analyses, we now have the opportunity to probe -induced responses more effectively, to not only learn what happens immediately after vaccination, but to monitor responses over time and utilize machine learning to eventually predict the human immune response to vaccines," said Dr. Scheuermann.

"We are optimistic about the outcome of these early stage findings. They provide important insights into the scale and complexity of the human immune system and how vaccines confer . With our network of academic and corporate partners, we aim to build on these findings and decode the human , giving the world the tools required to advance the development of future vaccines and therapies to defeat major global diseases," added Wayne C. Koff, PhD, President and CEO of the Human Vaccines Project.

Explore further: Ebola: Early immune response provides insight into vaccination

More information: www.humanvaccinesproject.org/

Related Stories

Ebola: Early immune response provides insight into vaccination

September 7, 2017
The latest outbreaks of emerging, dangerous pathogens, such as Ebola, MERS-CoV or Zika, emphasise the importance of the rapid development of effective vaccines. However, being able to predict the efficacy of new vaccines ...

Studying immune response to aluminum salts can explain how these chemicals boost vaccine's efficacy

June 28, 2017
Adjuvants are often included in vaccines to stimulate the immune system and so make a vaccine more effective. Now an A*STAR team, led by Alessandra Mortellaro from the Singapore Immunology Network, has explained a new immune ...

Study identifies genes linked to better immune response to flu vaccine

August 25, 2017
Yale experts and their partners in a national research consortium have identified several genes and gene clusters associated with the immune response to flu vaccination. The findings point to the prospect of using genetic ...

Research offers a new approach to improving HIV vaccines

June 4, 2015
In a scientific discovery that has significant implications for preventing HIV infections, researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) have identified a protein that could improve the body's ...

Researchers take an important step toward an HIV vaccine

May 17, 2017
Researchers from the University of Copenhagen have developed a strategy that can revolutionize vaccine design. The new strategy is used to develop vaccines that can prevent HIV infection and the development of AIDS.

A novel DNA vaccine design improves chances of inducing anti-tumor immunity

February 24, 2017
Scientists at The Wistar Institute and Inovio Pharmaceuticals, Inc. have devised a novel DNA vaccine approach through molecular design to improve the immune responses elicited against one of the most important cancer antigen ...

Recommended for you

A bad influence—the interplay between tumor cells and immune cells

October 16, 2018
Research at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ...

New immunotherapy targeting blood-clotting protein

October 15, 2018
Normally, the blood protein fibrin does not enter the brain. But in several neurological disorders, the blood-brain barrier—which keeps large molecules in the blood from entering the brain—becomes abnormally permeable, ...

Function of neutrophils during tumor progression unraveled

October 15, 2018
Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant sites and ...

Immune health maintained by meticulously ordered DNA

October 15, 2018
Walter and Eliza Hall Institute researchers have revealed how immune health is maintained by the exquisite organisation skills of a protein called Pax5.

Enzyme that triggers autoimmune responses from T-cells in patients with MS found

October 11, 2018
A team of researchers from Switzerland, the U.S. and Spain has isolated an enzyme that triggers an autoimmune response from T-cells in patients with MS. In their paper published in the journal Science Translational Medicine, ...

Scientists reveal new cystic fibrosis treatments work best in inflamed airways

October 11, 2018
A new UNC School of Medicine study shows that two cystic fibrosis (CF) drugs aimed at correcting the defected CFTR protein seem to be more effective when a patient's airway is inflamed. This is the first study to evaluate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.